US Venture Capital Off To Good Start After Record 2015; Tarveda Raises $38m
This article was originally published in Scrip
Executive Summary
US biotechnology companies raised a record-breaking $7.4bn in venture capital in 2015, and based on VC fundraising so far in January – including a $38m Series C round for Tarveda Therapeutics Inc. – 2016 looks like it may keep pace with last year.
You may also be interested in...
Refocusing Tarveda On Tumor-Targeted Mini-Drug Conjugates
Emerging Company Profile: Tarveda Therapeutics has refocused during the past 18 months on its Pentarin technology. The company has raised $91.8m to date, including a recent $30m Series D round, which it will use to produce human data that could make it attractive to investors or pharma partners.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.